Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells $1,248,000.00 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the transaction, the insider directly owned 936,410 shares in the company, valued at $5,843,198.40. This trade represents a 17.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $6.34 on Monday. The stock has a 50-day moving average price of $6.15 and a 200 day moving average price of $5.36. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -16.68 and a beta of 1.17. Taysha Gene Therapies, Inc. has a 12 month low of $2.34 and a 12 month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Research analysts expect that Taysha Gene Therapies, Inc. will post -0.49 EPS for the current year.

Analysts Set New Price Targets

TSHA has been the subject of a number of recent research reports. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. BMO Capital Markets upped their target price on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, June 23rd. Finally, Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $12.62.

Institutional Trading of Taysha Gene Therapies

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC boosted its stake in Taysha Gene Therapies by 325.6% during the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after acquiring an additional 82,545 shares during the last quarter. Rhumbline Advisers increased its stake in Taysha Gene Therapies by 13.5% in the second quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after purchasing an additional 27,794 shares in the last quarter. Prudential Financial Inc. raised its holdings in Taysha Gene Therapies by 50.5% in the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock worth $53,000 after purchasing an additional 7,650 shares during the period. Invesco Ltd. raised its holdings in Taysha Gene Therapies by 27.4% in the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock worth $470,000 after purchasing an additional 43,772 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Taysha Gene Therapies in the second quarter worth $184,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.